About Sudeep Pharma
Sudeep Pharma is a publicly listed company based in Vadodara (India) founded in 1989. It operates as a pharmaceutical excipients and ingredients are manufactured for multiple industries. Sudeep Pharma has raised $18.75 million across 1 funding round from investors including Nuvama, WhiteOak Capital Management and Dalmia Family Office Trust. The company has 377 employees. Its website sudeeppharma.com draws about 10 thousand monthly visits. Its Indian entity Sudeep Pharma Limited reported revenue of ₹511 Cr. Sudeep Pharma offers products and services including Calcium Phosphate, Calcium Carbonate, Iron Salts, and Magnesium Salts. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Excipient Production. Its competitors include Colorcon, Pfanstiehl, SPI Pharma, Scope Ingredients and Meggle Pharma and 5 more; 1 of its 10 listed competitors has raised funding.
Company details
Sudeep Pharma was founded in 1989 in Vadodara, India, where operations center on producing pharmaceutical excipients and ingredient solutions. Products are supplied to sectors including pharmaceuticals and beverages, with a portfolio that addresses specific industry needs. Quality standards are maintained through established processes, and solutions are developed to support customer requirements in these fields. The companys domain is sudeeppharma.com.
- Headquarters Vadodara, India
- Employees 377
- Stage Public
- SectorsHealthcare
- Website sudeeppharma.com
- Social LinkedIn
- Legal Name Sudeep Pharma Limited
- Market Cap₹11,332 Cr
SUDEEPPHRM · NSE
- Share Price₹1,003.30
+0.26% today
- Revenue₹642 Cr
FY 2025-26 · +27.9% YoY
- EBITDA₹223 Cr
Margin 34.7%
- Net Profit₹173 Cr
FY 2025-26 · +24.3% YoY
- P/E (TTM)61.9x
P/B 12.8x
- ROE25.4%
ROCE 27.9%
- Debt / Equity0.21
Interest cover 4.1x
- Total Equity Funding$18.75M (USD)
in 1 rounds
- Latest Funding Round$18.75M (USD), Series B
May 2025
- InvestorsNuvama
& 4 more
- Employee Count377
Associated legal entities of Sudeep Pharma
Sudeep Pharma is associated with 2 registered companies on The Company Check; the primary company is Sudeep Pharma Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sudeep Pharma Limited Listed CIN L24231GJ1989PLC013141 | Active | 21 Dec 1989 | Baroda, Gujarat | ₹511 Cr | 377 | 10 | View details |
| Sudeep Pharma Private Limited CIN U24231GJ1989PTC013141 | – | 21 Dec 1989 | Vadodara, Gujarat, India | – | – | – | View details |
Products & Services of Sudeep Pharma
Sudeep Pharma offers a comprehensive portfolio of products and services, including Calcium Phosphate, Calcium Carbonate, Iron Salts, and Magnesium Salts.
Serves as a binder in pharmaceutical and food formulations.
Provides calcium for nutrition and pharmaceutical applications.
Used in fortified foods and supplements for mineral delivery.
Supports formulations in pharmaceuticals and dietary products.
Funding Insights of Sudeep Pharma
Sudeep Pharma has successfully raised a total of $18.75M through 1 strategic funding round. The most recent funding activity was a Series B round of $18.75 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.75M
- Total Rounds 1
- Last Round Series B — $18.75M
- First Round $18.75M
(May 2025)
- Investors Count 5
All 1 funding rounds of Sudeep Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2025 | $18.75M | Series B | – | White Oak |
5 investors in total: 4 institutional and 1 angel.
Investors in Sudeep Pharma
Sudeep Pharma has secured backing from 5 investors, including institutional and angel investors. Prominent investors backing the company include Nuvama, WhiteOak Capital Management and Dalmia Family Office Trust.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment management and advisory services are provided in India. | 2017 | whiteoakindia.com | Mumbai, India | |
An integrated wealth management platform is operated by Nuvama. | 2008 | nuvama.com | Mumbai, India | |
MA Mukul Agrawal | - | – | unknown_f8830347f8e84592a | - |
- | – | dalmiafamilyofficetrust.tcc.mode | - | |
- | – | sanshifund.com | - |
Investor details for Sudeep Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Sudeep Pharma Limited (Sudeep Pharma)
Sudeep Pharma Limited is the primary company behind Sudeep Pharma. The board of Sudeep Pharma Limited currently have 8 directors; the longest-serving is Sujit Jaysukh Bhayani, appointed in 1995. 20 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sujit Jaysukh Bhayani DIN 01767427 | Managing Director | 01 Mar 1995 | 31 yrs 7 mo | Sudeep Pharma Limited |
| Shanil Sujit Bhayani DIN 08877823 | Whole-time director | 10 Dec 2021 | 4 yrs 10 mo | Sudeep Pharma Limited |
| Samaresh Parida DIN 01853823 | Director | 13 Sep 2024 | 2 yrs 1 mo | Sudeep Pharma Limited |
| Raghunandan Sathyanarayan Rao DIN 02263845 | Director | 13 Sep 2024 | 2 yrs 1 mo | Sudeep Pharma Limited |
| Sujit Gulati DIN 00177274 | Director | 13 Sep 2024 | 2 yrs 1 mo | Sudeep Pharma Limited |
| Reshma Suresh Patel DIN 00165162 | Director | 13 Sep 2024 | 2 yrs 1 mo | Sudeep Pharma Limited |
| Ajay Shrirang Kandelkar DIN 10773491 | Whole-time director | 13 Sep 2024 | 2 yrs 1 mo | Sudeep Pharma Limited |
| Milin Kaimas Mehta DIN 01297508 | Director | 26 Jun 2026 | 3 mo | Sudeep Pharma Limited |
IPO & Listings of Sudeep Pharma
Sudeep Pharma is a publicly listed company on the NSE with ticker symbol SUDEEPPHRM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Nov 2025
- Listed onBSE: 544619 · NSE: SUDEEPPHRM
- Listed entitySUDEEP PHARMA LIMITED
- Exchange sectorHealth technology
- ISININE0QPI01025
- Share price₹1,028.50 (+1.61% on the day) · 2026-10-14
- Market capitalisation₹11,455 Cr
- Price to earnings63.6
- EPS (diluted, trailing year)₹16.17
- Dividend yield0.15%
- Volume (last session)251,450
Financials of Sudeep Pharma
Exchange-reported figures of Sudeep Pharma Limited, the listed company behind Sudeep Pharma (NSE: SUDEEPPHRM).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 642 | 502 | 459 | 429 | 343 | 215 | 123 |
| Revenue growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| EBITDA | 223 | 191 | 182 | 90.16 | 67.47 | 44.08 | 25.38 |
| EBITDA margin | +34.7% | +38.1% | +39.7% | +21.0% | +19.7% | +20.5% | +20.6% |
| Profit before tax | 228 | 183 | 175 | 85.98 | 68.61 | 43.02 | 24.60 |
| Net profit | 173 | 139 | 133 | 62.38 | 50.08 | 33.27 | 18.04 |
| Net profit margin | +26.9% | +27.7% | +29.1% | +14.6% | +14.6% | +15.5% | +14.7% |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Balance sheet | |||||||
| Total assets | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Net worth | 883 | 493 | 356 | 223 | 163 | 114 | 80.95 |
| Total debt | 150 | 138 | 78.08 | 83.09 | 83.69 | 31.06 | 20.17 |
| Cash & bank | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Net working capital | 537 | 346 | 203 | 119 | 105 | 36.67 | 32.04 |
| Cash flow | |||||||
| Cash from operations | 69.55 | 48.73 | 65.69 | 48.40 | (2.98) | 35.28 | 9.87 |
| Cash from investing | (327) | (78.59) | (49.28) | (49.79) | (38.42) | (40.42) | (22.47) |
| Cash from financing | 247 | 52.70 | (12.74) | (9.78) | 50.92 | 13.00 | 12.45 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 158 | 182 | 172 | 163 | 125 | 158 | 116 | 149 |
| Revenue growth (YoY) | +26.7% | +15.7% | +49.2% | +9.3% | +55.9% | - | - | - |
| Other income | 5.45 | 6.42 | 6.84 | 10.17 | 5.16 | 3.76 | 2.44 | 1.87 |
| EBITDA | 54.91 | 62.60 | 59.98 | 55.47 | 43.88 | 58.78 | 39.30 | 63.47 |
| EBITDA margin | +34.7% | +34.3% | +34.8% | +34.1% | +35.1% | +37.3% | +34.0% | +42.7% |
| Depreciation | 4.00 | 3.88 | 3.86 | 3.81 | 3.25 | 2.83 | 2.67 | 2.58 |
| Interest | 2.06 | 2.44 | 1.17 | 2.28 | 1.71 | 1.85 | 1.41 | 1.05 |
| Profit before tax | 54.30 | 62.70 | 61.79 | 59.55 | 44.08 | 57.86 | 37.66 | 61.71 |
| Tax | 13.71 | 14.15 | 14.08 | 12.76 | 12.80 | 13.67 | 8.94 | 12.97 |
| Net profit | 40.59 | 48.55 | 47.71 | 46.79 | 31.28 | 44.19 | 28.72 | 48.74 |
| EPS (₹) | 3.59 | 4.38 | 4.29 | 4.20 | 2.84 | 4.07 | 2.65 | 4.49 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 339 | 357 | 344 | 404 | 345 | 218 |
| Revenue growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| EBITDA | 120 | 133 | 133 | 89.25 | 68.14 | 45.79 |
| EBITDA margin | +35.6% | +37.2% | +38.7% | +22.1% | +19.8% | +21.0% |
| Profit before tax | 145 | 129 | 132 | 90.77 | 70.40 | 44.96 |
| Net profit | 107 | 95.60 | 97.99 | 67.17 | 52.01 | 34.92 |
| Net profit margin | +31.7% | +26.8% | +28.5% | +16.6% | +15.1% | +16.0% |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Balance sheet | ||||||
| Total assets | 913 | 552 | 396 | 308 | 242 | 148 |
| Net worth | 786 | 430 | 335 | 237 | 168 | 116 |
| Total debt | 127 | 120 | 60.48 | 70.52 | 72.66 | 31.06 |
| Cash & bank | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Net working capital | 404 | 265 | 180 | 128 | 105 | 34.37 |
| Cash flow | ||||||
| Cash from operations | 96.02 | 59.15 | 59.05 | 42.31 | (5.33) | 35.81 |
| Cash from investing | (367) | (91.59) | (40.67) | (40.71) | (27.97) | (44.71) |
| Cash from financing | 242 | 54.20 | (16.14) | (10.11) | 39.98 | 13.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 106 | 80.17 | 90.28 | 87.88 | 80.17 | 105 | 83.48 | 106 |
| Revenue growth (YoY) | +31.8% | -23.5% | +8.2% | -17.3% | +29.1% | - | - | - |
| Other income | 9.80 | 9.62 | 9.44 | 12.83 | 6.62 | 3.10 | 2.29 | 1.44 |
| Total expenses | 66.49 | 51.28 | 60.67 | 57.00 | 49.78 | 59.39 | 57.02 | 66.10 |
| EBITDA | 39.19 | 28.89 | 29.61 | 30.88 | 30.39 | 45.46 | 26.46 | 40.20 |
| EBITDA margin | +37.1% | +36.0% | +32.8% | +35.1% | +37.9% | +43.4% | +31.7% | +37.8% |
| Depreciation | 1.83 | 1.79 | 1.79 | 1.77 | 1.75 | 1.71 | 1.53 | 1.47 |
| Interest | 1.76 | 1.97 | 0.63 | 2.03 | 1.44 | 1.58 | 1.25 | 0.71 |
| Profit before tax | 45.40 | 34.75 | 36.63 | 39.91 | 33.82 | 45.27 | 25.97 | 39.46 |
| Tax | 11.58 | 8.98 | 9.76 | 10.17 | 8.63 | 12.15 | 5.34 | 10.02 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 158 | 182 | 172 | 163 | 125 | 158 | 116 | 149 |
| Revenue growth (YoY) | +26.7% | +15.7% | +49.2% | +9.3% | +55.9% | - | - | - |
| Other income | 5.45 | 6.42 | 6.84 | 10.17 | 5.16 | 3.76 | 2.44 | 1.87 |
| EBITDA | 54.91 | 62.60 | 59.98 | 55.47 | 43.88 | 58.78 | 39.30 | 63.47 |
| EBITDA margin | +34.7% | +34.3% | +34.8% | +34.1% | +35.1% | +37.3% | +34.0% | +42.7% |
| Depreciation | 4.00 | 3.88 | 3.86 | 3.81 | 3.25 | 2.83 | 2.67 | 2.58 |
| Interest | 2.06 | 2.44 | 1.17 | 2.28 | 1.71 | 1.85 | 1.41 | 1.05 |
| Profit before tax | 54.30 | 62.70 | 61.79 | 59.55 | 44.08 | 57.86 | 37.66 | 61.71 |
| Tax | 13.71 | 14.15 | 14.08 | 12.76 | 12.80 | 13.67 | 8.94 | 12.97 |
| Net profit | 40.59 | 48.55 | 47.71 | 46.79 | 31.28 | 44.19 | 28.72 | 48.74 |
| EPS (₹) | 3.59 | 4.38 | 4.29 | 4.20 | 2.84 | 4.07 | 2.65 | 4.49 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 642 | 502 | 459 | 429 | 343 | 215 | 123 |
| Revenue growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| Other income | 28.59 | 9.33 | 6.10 | 9.52 | 7.39 | 3.44 | 3.22 |
| Total expenses | 419 | 311 | 277 | 339 | 276 | 171 | 97.63 |
| Employee cost | 51.89 | 38.34 | 29.41 | 66.10 | 15.55 | 11.46 | 9.34 |
| EBITDA | 223 | 191 | 182 | 90.16 | 67.47 | 44.08 | 25.38 |
| EBITDA margin | +34.7% | +38.1% | +39.7% | +21.0% | +19.7% | +20.5% | +20.6% |
| Depreciation | 14.81 | 10.59 | 9.01 | 7.92 | 4.53 | 3.53 | 3.07 |
| Interest | 8.50 | 6.90 | 4.74 | 5.78 | 1.72 | 0.97 | 0.93 |
| Profit before tax | 228 | 183 | 175 | 85.98 | 68.61 | 43.02 | 24.60 |
| Tax | 53.79 | 44.12 | 41.63 | 23.66 | 18.43 | 9.68 | 6.56 |
| Net profit | 173 | 139 | 133 | 62.38 | 50.08 | 33.27 | 18.04 |
| Net profit margin | +26.9% | +27.7% | +29.1% | +14.6% | +14.6% | +15.5% | +14.7% |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.29 | 11.98 | 1.41 | 1.41 | 1.41 | 1.41 | 1.41 |
| Reserves & surplus | 872 | 481 | 355 | 222 | 162 | 113 | 79.54 |
| Shareholders' funds (net worth) | 883 | 493 | 356 | 223 | 163 | 114 | 80.95 |
| Minority interest | 14.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 148 | 135 | 75.03 | 82.26 | 83.69 | 31.06 | 17.09 |
| Unsecured loans | 2.13 | 2.30 | 3.05 | 0.83 | 0.00 | 0.00 | 3.08 |
| Total debt | 150 | 138 | 78.08 | 83.09 | 83.69 | 31.06 | 20.17 |
| Total liabilities | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Assets | |||||||
| Gross block | 378 | 216 | 197 | 166 | 157 | 83.31 | 71.80 |
| Net block | 337 | 189 | 180 | 158 | 137 | 67.65 | 59.58 |
| Capital work in progress | 185 | 88.22 | 44.66 | 25.97 | 8.13 | 24.00 | 8.16 |
| Investments | 0.00 | 0.14 | 0.13 | 3.03 | 0.00 | 19.10 | 6.00 |
| Inventories | 216 | 129 | 66.58 | 71.00 | 36.54 | 17.47 | 9.50 |
| Sundry debtors | 228 | 185 | 145 | 93.71 | 107 | 55.18 | 30.32 |
| Cash & bank balances | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Loans & advances | 65.73 | 58.15 | 50.11 | 51.98 | 31.68 | 14.89 | 12.39 |
| Total current assets | 624 | 424 | 275 | 227 | 197 | 99.50 | 56.31 |
| Total current liabilities | 87.17 | 78.41 | 72.58 | 108 | 91.53 | 62.83 | 24.27 |
| Net working capital | 537 | 346 | 203 | 119 | 105 | 36.67 | 32.04 |
| Total assets | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 36.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 | 4.25 |
| Net cash from operating activities | 69.55 | 48.73 | 65.69 | 48.40 | (2.98) | 35.28 | 9.87 |
| Net cash from investing activities | (327) | (78.59) | (49.28) | (49.79) | (38.42) | (40.42) | (22.47) |
| Net cash from financing activities | 247 | 52.70 | (12.74) | (9.78) | 50.92 | 13.00 | 12.45 |
| Net change in cash | (10.07) | 22.83 | 3.67 | (11.17) | 9.52 | 7.86 | (0.16) |
| Closing cash | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| EBITDA growth | +16.6% | +4.7% | +102.4% | +33.6% | +53.1% | +73.7% | - |
| PBT growth | +24.7% | +4.6% | +103.3% | +25.3% | +59.5% | +74.9% | +9997.0% |
| Net income growth | +24.3% | +4.3% | +113.9% | +24.6% | +50.5% | +84.4% | - |
| Revenue CAGR (3Y) | +14.4% | +13.5% | +28.8% | +51.6% | - | - | - |
| EBITDA CAGR (3Y) | +35.2% | +41.5% | +60.6% | +52.6% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +27.1% | +27.6% | +29.0% | +14.5% | +14.6% | +15.5% | +14.7% |
| Return on capital employed | +27.9% | +35.5% | +48.4% | +33.1% | +35.7% | +35.4% | +25.0% |
| Return on net worth | +25.4% | +32.8% | +46.0% | +32.2% | +36.2% | +34.2% | +22.3% |
| Debt / equity | 0.21 | 0.25 | 0.28 | 0.43 | 0.41 | 0.26 | 0.25 |
| Long-term debt / equity | 0.06 | 0.06 | 0.06 | 0.13 | 0.15 | 0.11 | 0.10 |
| Interest cover | 4.09 | 3.82 | 2.73 | 7.03 | 2.73 | 2.39 | 4.17 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.16 | 2.43 | 2.53 | 2.65 | 2.86 | 2.77 | 1.71 |
| Inventory turnover | 3.73 | 5.14 | 6.68 | 7.97 | 12.70 | 15.95 | 12.95 |
| Debtors turnover | 3.11 | 3.04 | 3.85 | 4.27 | 4.23 | 5.03 | 4.06 |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 78.21 | 50.48 | 252.69 | 158.47 | 1,159.15 | 810.48 | 574.46 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 106 | 80.17 | 90.28 | 87.88 | 80.17 | 105 | 83.48 | 106 |
| Revenue growth (YoY) | +31.8% | -23.5% | +8.2% | -17.3% | +29.1% | - | - | - |
| Other income | 9.80 | 9.62 | 9.44 | 12.83 | 6.62 | 3.10 | 2.29 | 1.44 |
| Total expenses | 66.49 | 51.28 | 60.67 | 57.00 | 49.78 | 59.39 | 57.02 | 66.10 |
| EBITDA | 39.19 | 28.89 | 29.61 | 30.88 | 30.39 | 45.46 | 26.46 | 40.20 |
| EBITDA margin | +37.1% | +36.0% | +32.8% | +35.1% | +37.9% | +43.4% | +31.7% | +37.8% |
| Depreciation | 1.83 | 1.79 | 1.79 | 1.77 | 1.75 | 1.71 | 1.53 | 1.47 |
| Interest | 1.76 | 1.97 | 0.63 | 2.03 | 1.44 | 1.58 | 1.25 | 0.71 |
| Profit before tax | 45.40 | 34.75 | 36.63 | 39.91 | 33.82 | 45.27 | 25.97 | 39.46 |
| Tax | 11.58 | 8.98 | 9.76 | 10.17 | 8.63 | 12.15 | 5.34 | 10.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 339 | 357 | 344 | 404 | 345 | 218 |
| Revenue growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| Other income | 38.50 | 8.38 | 8.20 | 11.18 | 8.08 | 3.67 |
| Total expenses | 218 | 224 | 211 | 315 | 277 | 172 |
| Employee cost | 28.95 | 26.06 | 20.22 | 60.79 | 13.55 | 11.46 |
| EBITDA | 120 | 133 | 133 | 89.25 | 68.14 | 45.79 |
| EBITDA margin | +35.6% | +37.2% | +38.7% | +22.1% | +19.8% | +21.0% |
| Depreciation | 7.11 | 6.12 | 5.15 | 4.83 | 4.19 | 3.53 |
| Interest | 6.73 | 5.68 | 3.68 | 4.83 | 1.63 | 0.97 |
| Profit before tax | 145 | 129 | 132 | 90.77 | 70.40 | 44.96 |
| Tax | 37.51 | 33.66 | 34.23 | 23.60 | 18.10 | 9.97 |
| Net profit | 107 | 95.60 | 97.99 | 67.17 | 52.01 | 34.92 |
| Net profit margin | +31.7% | +26.8% | +28.5% | +16.6% | +15.1% | +16.0% |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 11.29 | 11.98 | 1.41 | 1.41 | 1.41 | 1.41 |
| Reserves & surplus | 775 | 418 | 333 | 235 | 167 | 115 |
| Shareholders' funds (net worth) | 786 | 430 | 335 | 237 | 168 | 116 |
| Secured loans | 125 | 119 | 58.05 | 69.69 | 72.66 | 31.06 |
| Unsecured loans | 1.72 | 1.78 | 2.43 | 0.83 | 0.00 | 0.00 |
| Total debt | 127 | 120 | 60.48 | 70.52 | 72.66 | 31.06 |
| Total liabilities | 913 | 552 | 396 | 308 | 242 | 148 |
| Assets | ||||||
| Gross block | 124 | 120 | 106 | 94.64 | 139 | 83.31 |
| Net block | 102 | 105 | 95.89 | 89.82 | 120 | 67.65 |
| Capital work in progress | 161 | 87.71 | 43.50 | 25.59 | 4.38 | 23.21 |
| Investments | 32.07 | 31.51 | 28.75 | 18.70 | 15.11 | 24.21 |
| Inventories | 131 | 64.60 | 45.42 | 52.40 | 26.33 | 15.10 |
| Sundry debtors | 80.13 | 162 | 141 | 126 | 123 | 58.14 |
| Cash & bank balances | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Loans & advances | 157 | 40.70 | 35.40 | 47.81 | 27.71 | 14.86 |
| Total current assets | 458 | 313 | 231 | 233 | 192 | 96.29 |
| Total current liabilities | 53.75 | 48.20 | 50.96 | 105 | 86.61 | 61.92 |
| Net working capital | 404 | 265 | 180 | 128 | 105 | 34.37 |
| Total assets | 913 | 552 | 396 | 308 | 242 | 148 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 30.35 | 8.59 | 6.35 | 14.87 | 8.19 | 4.10 |
| Net cash from operating activities | 96.02 | 59.15 | 59.05 | 42.31 | (5.33) | 35.81 |
| Net cash from investing activities | (367) | (91.59) | (40.67) | (40.71) | (27.97) | (44.71) |
| Net cash from financing activities | 242 | 54.20 | (16.14) | (10.11) | 39.98 | 13.00 |
| Net change in cash | (28.16) | 21.75 | 2.24 | (8.52) | 6.68 | 4.09 |
| Closing cash | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| EBITDA growth | -9.3% | -0.1% | +48.9% | +31.0% | +48.8% | - |
| PBT growth | +12.1% | -2.2% | +45.7% | +28.9% | +56.6% | +9997.0% |
| Net income growth | +12.4% | -2.4% | +45.9% | +29.2% | +48.9% | - |
| Revenue CAGR (3Y) | -5.7% | +1.1% | +16.4% | - | - | - |
| EBITDA CAGR (3Y) | +10.5% | +24.9% | +42.7% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +31.8% | +26.8% | +28.5% | +16.6% | +15.2% | +16.1% |
| Return on capital employed | +20.7% | +28.5% | +38.7% | +34.8% | +37.0% | +36.7% |
| Return on net worth | +17.7% | +25.1% | +34.3% | +33.2% | +36.8% | +35.5% |
| Debt / equity | 0.20 | 0.24 | 0.23 | 0.35 | 0.36 | 0.26 |
| Long-term debt / equity | 0.06 | 0.06 | 0.03 | 0.07 | 0.11 | 0.11 |
| Interest cover | 5.94 | 4.48 | 2.88 | 5.72 | 2.55 | 2.30 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 2.77 | 3.16 | 3.43 | 3.46 | 3.11 | 2.81 |
| Inventory turnover | 3.47 | 6.48 | 7.03 | 10.26 | 16.65 | 17.71 |
| Debtors turnover | 2.79 | 2.35 | 2.57 | 3.24 | 3.81 | 4.93 |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 69.59 | 44.01 | 2,374.56 | 1,681.07 | 1,193.96 | 822.76 |
Timeline of Sudeep Pharma
3 dated milestones of Sudeep Pharma across 36 years, from founding to its latest funding, stage changes and deals.
- Founded Sudeep Pharma is founded.
- Funding First funding round of $18.7M.
- IPO Lists on the stock exchange (IPO).
Competitors of Sudeep Pharma
Sudeep Pharma has 10 listed competitors in our database, 1 of them funded. They include Colorcon, Pfanstiehl, SPI Pharma, Scope Ingredients and Meggle Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| colorcon.com | 1961 | Harleysville, United States | – | 443 | Developer of specialty excipients and corporate-backed venture capital fund focused on healthcare startups | |
| pfanstiehl.com | 1919 | Waukegan, United States | $6.7M | – | APIs, injectable excipients, and bioprocessing solutions are manufactured. | |
| spipharma.com | 2000 | Wilmington, United States | – | 22 | Excipient products and formulations are manufactured for pharmaceutical uses. | |
| scope-india.com | 1959 | Chennai, India | – | 89 | Formulations, warehousing, and logistics services for pharmaceuticals are provided. | |
| meggle-pharma.com | 2005 | Wasserburg Am Inn, Germany | – | 33 | Develops and manufactures pharmaceutical excipients for the industry. | |
| jrspharma.com | 1878 | Baden Baden, Germany | – | – | Supplies excipients, coatings, and technical services for health sciences worldwide. | |
| crestcellulose.com | 2011 | Hyderabad, India | – | 77 | Pharmaceutical excipients and food ingredients are developed and manufactured. | |
| dfepharma.com | 2011 | Goch, Germany | – | – | Developer and manufacturer of excipients for oral solid dosage forms and dry powder inhalations | |
| vikramthermo.com | 1984 | Ahmedabad, India | – | 107 | Manufacturer of excipients for small molecules | |
| boai-nky.com | 1987 | Jiaozuo, China | – | – | Develops and manufactures pharmaceutical excipients, specializing in PVP products. |
Detailed competitors of Sudeep Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sudeep Pharma
The website of Sudeep Pharma (sudeeppharma.com) receives about 10K visits a month.
- Monthly visits10K
▼ 76.2% vs previous month
Websites whose visitors overlap most with Sudeep Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sudeepgroup.com | 100% | – | #6,485,392 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as Sudeep Pharma (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sudeep Pharma
Complete news archive for Sudeep Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sudeep Pharma
Sudeep Pharma was founded in 1989 and raised its 1st funding round 36 years after it was founded.
Sudeep Pharma is headquartered in Vadodara, India. It is registered at Vadodara, Gujarat, India.
Sudeep Pharma is a funded company, having raised a total of $18.75M across 1 funding round to date. The company's 1st funding round was a Series B of $18.75M, raised on May 2025.
Sudeep Pharma has 377 employees.
The primary company behind Sudeep Pharma, Sudeep Pharma Limited, reported revenue of ₹511 Cr for FY 2025, up 10% year on year.
Sudeep Pharma was founded in 1989 in Vadodara, India, where operations center on producing pharmaceutical excipients and ingredient solutions. Products are supplied to sectors including pharmaceuticals and beverages, with a portfolio that addresses specific industry needs. Quality standards are maintained through established processes, and solutions are developed to support customer requirements in these fields. The companys domain is sudeeppharma.com.
Sudeep Pharma's top competitors include Colorcon, DFE Pharma and Crest Cellulose.
Sudeep Pharma offers Calcium Phosphate, Calcium Carbonate, Iron Salts, and Magnesium Salts.
Yes, Sudeep Pharma is publicly traded on NSE under the ticker symbol SUDEEPPHRM.
Sudeep Pharma has 5 investors. Key investors include Nuvama, WhiteOak Capital Management, Dalmia Family Office Trust, Mukul Agrawal, and Sanshi Fund.
Sudeep Pharma operates through Sudeep Pharma Limited.
The legal entities of Sudeep Pharma currently have 10 directors, including Shanil Sujit Bhayani, Sujit Jaysukh Bhayani, Dimple Ashwinbhai Mehta and others.